MErCuRIC will be presented at the American Society of Clinical Oncology (ASCO) 2015 meeting, 29 May – 02 June 2015, in Chicago.
A poster entitled ‘MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients’ will be included in the Gastrointestinal (Colorectal) Cancer poster session.
Recent News
Project Info
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.